주문제작 서비스 문의
찾으시는 제품이 저희 사이트에 없으신가요? 단백질 주문 제작 서비스를 이용해보세요!
주문제작 서비스 문의 >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
As AACR 2024 concluded, we witnessed exciting breakthroughs in the field of antibody-drug conjugates (ADCs). Notably, bispecific antibody-drug conjugates (BsADCs) emerged as a focal point of attention. We are pleased to share some of the noteworthy therapies presented at the conference:
Selected Research Highlights:
- Innovent IBI3001: A potentially first-in-class bispecific ADC against B7-H3 and Her2 that is site-specifically glycan-conjugate for multiple solid tumors. IBI3001 showed strong anti-tumor efficacy in vitro and in vivo across multiple solid tumors and is well tolerated.
- Innovent IBI334: A novel ADCC-enhanced B7-H3/Her2 bispecific antibody, which showed better tumor growth inhibition in vitro and in vivo than Her2 monoclonal antibody and c-met/Her2 bispecific antibody benchmarks.
- Alphamab JSKN003-101: An anti-HER2 bispecific ADC for the treatment of HER2-expressing advanced solid tumors. According to data, JSKN003 exhibited a favorable tolerability, and safety profile and encouraged preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors.
ADC target proteins from ACROBiosystems (partial)
FRα | Nectin-4 | c-MET | B7-H3 |
B7-H4 | ENPP3 | LRRC15 | HER3 |
We provide a wide range of solutions to support ADC development. Download our ebook to discover ADC development reagents that can assist you in your ADC development journey:
This web search service is supported by Google Inc.